ABBV

$294.891.41%4.10

Nachbörslich: 295.30+0.41 +0.14%

Abbvie Inc (ABBV)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$290.79

Offen:

$292.00

24-Stunden-Volumen:

6,896,435

Relatives Volumen:

1.48

Marktkapitalisierung:

$521.11B

Einnahmen:

$62.82B

Nettoeinkommen (Verlust:

$3.60B

KGV:

145.45

EPS:

$2.03

Netto-Cashflow:

$19.98B

1W Leistung:

+3.24%

1M Leistung:

+12.73%

6M Leistung:

+39.55%

1Y Leistung:

+29.22%

1-Tages-Spanne:

$291.01$298.74

1-Wochen-Bereich:

$281.23$298.74

52-Wochen-Spanne:

$190.75$298.74

Abbvie Inc Aktie (ABBV) Unternehmensprofil

Firmenname

Abbvie Inc

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(847) 932-7900

Adresse

1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, USA

Mitarbeiter

57,000

@abbvie

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

ABBV-Diskussionen auf X

ABBV vs. LLY, JNJ, MRK, NVS vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABBV Abbvie Inc	$294.89	$521.11B	$62.82B	$3.60B	$19.98B	$2.03
LLY Lilly Eli Co	$1,417.54	$1.26T	$72.25B	$25.28B	$10.37B	$27.78
JNJ Johnson Johnson	$273.20	$657.68B	$97.93B	$21.04B	$17.80B	$8.63
MRK Merck Co Inc	$149.52	$368.89B	$65.51B	$8.93B	$14.12B	$3.55
NVS Novartis Ag Adr	$160.79	$303.67B	$54.66B	$13.58B	$16.05B	$7.02

Abbvie Inc Aktie (ABBV) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-08-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2026-08-05	Hochstufung	Erste Group	Hold → Buy
2026-04-30	Hochstufung	BofA Securities	Neutral → Buy
2026-04-21	Eingeleitet	Canaccord Genuity	Buy
2026-02-25	Eingeleitet	RBC Capital Mkts	Outperform
2026-02-20	Eingeleitet	Barclays	Overweight
2026-01-08	Herabstufung	Wolfe Research	Outperform → Peer Perform
2026-01-07	Resumed	UBS	Neutral
2025-12-10	Hochstufung	HSBC Securities	Hold → Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-11-04	Herabstufung	DZ Bank	Buy → Hold
2025-10-14	Herabstufung	Erste Group	Buy → Hold
2025-10-01	Herabstufung	HSBC Securities	Buy → Hold
2025-09-17	Hochstufung	Berenberg	Hold → Buy
2025-08-12	Resumed	Piper Sandler	Overweight
2025-08-07	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-05-14	Herabstufung	Citigroup	Buy → Neutral
2025-04-22	Eingeleitet	Cantor Fitzgerald	Overweight
2024-12-10	Resumed	BofA Securities	Neutral
2024-12-05	Herabstufung	Daiwa Securities	Outperform → Neutral
2024-11-22	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-04	Hochstufung	Argus	Hold → Buy
2024-10-17	Eingeleitet	Bernstein	Mkt Perform
2024-06-05	Hochstufung	HSBC Securities	Hold → Buy
2024-05-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-01-29	Hochstufung	William Blair	Mkt Perform → Outperform
2023-12-18	Herabstufung	HSBC Securities	Buy → Hold
2023-12-11	Hochstufung	Goldman	Neutral → Buy
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-10-30	Hochstufung	Barclays	Equal Weight → Overweight
2023-10-20	Resumed	UBS	Neutral
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-07-25	Eingeleitet	William Blair	Mkt Perform
2023-07-14	Eingeleitet	HSBC Securities	Buy
2023-04-05	Herabstufung	Argus	Buy → Hold
2023-03-01	Eingeleitet	Guggenheim	Buy
2023-02-22	Herabstufung	Wolfe Research	Outperform → Peer Perform
2023-02-10	Hochstufung	SVB Securities	Underperform → Market Perform
2022-11-18	Eingeleitet	Credit Suisse	Outperform
2022-11-08	Herabstufung	Societe Generale	Buy → Hold
2022-08-01	Herabstufung	Atlantic Equities	Overweight → Neutral
2022-05-23	Eingeleitet	SVB Leerink	Underperform
2022-05-06	Herabstufung	Daiwa Securities	Outperform → Neutral
2022-04-06	Resumed	Morgan Stanley	Overweight
2022-02-28	Herabstufung	UBS	Buy → Neutral
2022-02-03	Bestätigt	BMO Capital Markets	Outperform
2022-02-03	Bestätigt	Barclays	Equal Weight
2022-02-03	Bestätigt	BofA Securities	Neutral
2022-02-03	Bestätigt	Goldman	Neutral
2022-01-13	Eingeleitet	Redburn	Buy
2022-01-12	Bestätigt	BMO Capital Markets	Outperform
2021-12-09	Resumed	Wells Fargo	Overweight
2021-11-23	Hochstufung	Societe Generale	Hold → Buy
2021-07-27	Resumed	Truist	Buy
2021-04-07	Resumed	RBC Capital Mkts	Outperform
2020-11-10	Resumed	Bernstein	Outperform
2020-09-29	Eingeleitet	Berenberg	Hold
2020-06-23	Hochstufung	Atlantic Equities	Neutral → Overweight
2020-06-09	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-06-02	Hochstufung	Argus	Hold → Buy
2020-05-18	Resumed	BofA/Merrill	Neutral
2020-05-12	Hochstufung	JP Morgan	Neutral → Overweight
2020-05-11	Resumed	Morgan Stanley	Overweight
2020-04-20	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2020-03-23	Herabstufung	Societe Generale	Buy → Hold
2020-02-27	Eingeleitet	Barclays	Equal Weight
2020-02-06	Eingeleitet	Mizuho	Buy
2020-01-07	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-12-26	Bestätigt	Cowen	Outperform
2019-09-26	Hochstufung	Citigroup	Neutral → Buy
2019-08-20	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-27	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-06-26	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-05-28	Eingeleitet	Goldman	Neutral
2019-04-29	Hochstufung	BMO Capital Markets	Underperform → Market Perform

Finanzdaten der Abbvie Inc-Aktie (ABBV)

Umsatz

Nettogewinn

Free Cashflow

ENV

Abbvie Inc-Aktie (ABBV) Insiderhandel

Donoghoe NicholasAug 14 '26
EVP, CHIEF BUS/STRAT OFFICER
Transaktion
Sale
Kosten
$250.00
#Aktien
32,710
Wert ($)
8,177,500
#Aktien Gesamt
74,430
NICHOLAS DONOGHOEAug 14 '26
Officer
Transaktion
Proposed Sale
Kosten
$250.00
#Aktien
32,710
Wert ($)
8,177,500
#Aktien Gesamt
0
ROBERT J ALPERNMay 26 '26
Director
Transaktion
Proposed Sale
Kosten
$214.00
#Aktien
13,000
Wert ($)
2,781,991
#Aktien Gesamt
0
Purdue David RyanMar 04 '26
SVP, Controller
Transaktion
Sale
Kosten
$233.56
#Aktien
5,230
Wert ($)
1,221,519
#Aktien Gesamt
2,654
David R. PurdueMar 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$233.56
#Aktien
5,230
Wert ($)
1,221,519
#Aktien Gesamt
0
Siatis Perry CMar 02 '26
EVP, GC AND SECRETARY
Transaktion
Sale
Kosten
$234.39
#Aktien
18,668
Wert ($)
4,375,549
#Aktien Gesamt
4,619
PERRY C SIATISMar 02 '26
Officer
Transaktion
Proposed Sale
Kosten
$234.39
#Aktien
18,668
Wert ($)
4,375,585
#Aktien Gesamt
0
Siatis Perry CFeb 25 '26
EVP, GC AND SECRETARY
Transaktion
Option Exercise
Kosten
$172.62
#Aktien
22,381
Wert ($)
3,863,458
#Aktien Gesamt
60,518
Siatis Perry CFeb 25 '26
EVP, GC AND SECRETARY
Transaktion
Sale
Kosten
$230.00
#Aktien
22,381
Wert ($)
5,147,630
#Aktien Gesamt
38,137
PERRY C SIATISFeb 25 '26
Officer
Transaktion
Proposed Sale
Kosten
$230.00
#Aktien
22,381
Wert ($)
5,147,630
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 14 '26	Sale	$250.00	32,710	8,177,500	74,430
NICHOLAS DONOGHOE	Officer	Aug 14 '26	Proposed Sale	$250.00	32,710	8,177,500	0
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	$214.00	13,000	2,781,991	0
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	$233.56	5,230	1,221,519	2,654
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	$233.56	5,230	1,221,519	0
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	$234.39	18,668	4,375,549	4,619
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	$234.39	18,668	4,375,585	0
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	$172.62	22,381	3,863,458	60,518
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	$230.00	22,381	5,147,630	38,137
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	$230.00	22,381	5,147,630	0

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

Oct 30, 2026

Pre-Markets in Red on Massive AI Spending Concerns - Zacks Investment Research

Oct 30, 2026

Pre-Markets Spooked on Questions Regarding AI, Oil Prices - Zacks Investment Research

Oct 30, 2026

Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings - Zacks Investment Research

Oct 30, 2026

AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

AbbVie stock hits all-time high at 291.65 USD - Investing.com

Oct 29, 2026

Oct 28, 2026

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 28, 2026

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Oct 28, 2026

Arcutis Appoints Rob Scott, MD to Board of Directors - GlobeNewswire Inc.

Oct 28, 2026

AbbVie files etentamig application: what it means for AbbVie stock - ad-hoc-news.de

Oct 28, 2026

AbbVie: Still Strong Growth, But Patent Cliff Getting Closer (NYSE:ABBV) - Seeking Alpha

Oct 28, 2026

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

AbbVie announces Q3 2026 earnings call while stock holds steady - Traders Union

Oct 27, 2026

I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend - CNBC

Oct 27, 2026

AbbVie hits record highs with strong 2026 outlo... - Pluang

Oct 27, 2026

AbbVie Files FDA BLA for Etentamig in Multiple Myeloma, Ticker A - GuruFocus

Oct 27, 2026

AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy) (NYSE:ABBV) - Seeking Alpha

Oct 27, 2026

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research

Oct 27, 2026

Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings - Zacks Investment Research

Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research

Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView

Oct 27, 2026

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026

AbbVie (ABBV) Q3 2026 Preview: EPS Est. $3.78, Reports October 30 - AlphaStreet

Oct 26, 2026

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30 - 24/7 Wall St.

Oct 26, 2026

Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? - The Motley Fool

Oct 26, 2026

AbbVie wins Crohn's approval: what it means for AbbVie stock - ad-hoc-news.de

Oct 26, 2026

Should You Invest in the iShares U.S. Healthcare ETF (IYH)? - Zacks Investment Research

Oct 26, 2026

Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy - The Motley Fool

Oct 26, 2026

Oct 24, 2026

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool

Oct 24, 2026

Oct 23, 2026

BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research

Oct 23, 2026

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 23, 2026

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 23, 2026

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool

Oct 23, 2026

Oct 22, 2026

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Oct 22, 2026

Oct 21, 2026

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF - The Motley Fool

Oct 21, 2026

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Oct 21, 2026

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 21, 2026

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research

Oct 21, 2026

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News

Oct 20, 2026

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool

Oct 20, 2026

AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290 - ad-hoc-news.de

Oct 20, 2026

Oct 19, 2026

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.

Oct 19, 2026

AbbVie Inc. (ABBV80.BK) stock price, news, quote and history - Yahoo Finance Singapore

Oct 19, 2026

AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts - Yahoo Finance

Oct 19, 2026

Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - The Globe and Mail

Oct 19, 2026

AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05 - ad-hoc-news.de

Oct 19, 2026

AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying? - Yahoo Finance

Oct 19, 2026

Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research

Oct 19, 2026

AbbVie ABBV-466 Achieves 40.5% Crohn's Remission - grafa.com

Oct 19, 2026

Ähnlich wie ABBV